486Gabriel
430
orverymuchimproveduponcompletinga6-week MontgomeryandAsberg,1979]score were
lamotrigineaugmentationtrial.Twosmall,placebo- included.ModifiedcriteriafromThaseandRush
controlledtrialsalsoprovideevidencefortheanti- [1997]wereusedtoclassifytreatment-resistantdepres-
depressantefficacyoflamotrigine.Inthefirstcon- sion(TRD):Grade1,absenceofresponsetoone
trolled trial (n523),lamotrigine was superior to antidepressant;Grade2,absenceofresponsetotwoor
placeboinpatientsreceivingfluoxetineforresistant moreantidepressants,oneofthemfromadifferent
depression. Patients were treated with fluoxetine, group;Grade3,absenceofresponsetocombination
20mg/day,andconcomitantlyrandomlyassignedto and/oraugmentationstrategy;Grade4,Grade31
receiveeitherlamotrigineorplacebofor6weeks.Both absenceofresponsetoanirreversiblemonoamine
patientswithmajordepressivedisorderandbipolarII oxidase inhibitor; Grade 5, Grade 31absence of
disorderwereenrolledinthestudy.ClinicalGlobal responsetoelectroconvulsivetherapy(ECT;Table1).
ImpressionSeverityscale(CGI-S)scoresimprovedin Allpatientswereratedasmoderatelytoseverelyill
patientswithmajordepressivedisorderandthosewith prior to the adjunctive treatment and functioning
bipolarIIdisorderinthelamotrigine-treatedgroup poorly,andthreepatientshadalsofailedECTand/or
[Barbosa et al., 2003]. In the second randomized, transcranialmagneticstimulationtrials,aswellasthe
placebo-controlledstudy,lamotriginewasstudiedin antidepressantstrials(Table1).Patientswithpsychotic
patients(n540)withnonresistantunipolardepression.
disorders,alcohol or drugabuse,andeating disorders
Allpatientsweretreatedwithparoxetine.Howeverthe wereexcluded,andallpatientsremainedcompliant
paroxetine–lamotrigineadjunctivegroupdemonstrated withtheadjuctivetreatmentoflamotrigineforatleast
moresignificantimprovementoncoredepressive 6months.Patientsprovidedinformedconsent,ap-
symptomsasreflectedbyHamiltonDepressionScale provedbytheUniversityofCalgaryConjointScientific
(HAM-D)itemsfordepressedmood,guiltfeelings, andEthicsBoard.
work,andinterest[Normannetal.,2002].Alsoina Lamotriginewasaddedtoexistingantidepressants,
morerecentretrospectivechartreviewoftheefficacy andthedosewastitrated,accordingtoclinicalresponse
andtolerabilityoflamotrigineasanaugmentationdrug andtolerance,with25-to50-mgincrementsevery
intreatment-resistantunipolardepression,76%of 2weeks,toamaximumdoseof200mg/day.Werecorded
(n525)
patients wereratedasimproved[Rochaand patients’demographicdataandscoresofeffectiveness
Hara,2003].Lamotriginewas,however,evaluatedfor measurescompletedprospectivelyinpatients’chartsin
itsantidepressantefficacyandsafetyinunipolar follow-upvisitsforatleast6monthsofadjuvant
depressioninanumberofGlaxoSmithKline-spon- treatment.Efficacymeasuresincludedchangesofthe
sored,multicenter,placebo-controlled,randomized followingscalesatbaseline(beforeaddinglamotri-
trials.Althoughsomeofthesetrialsreportedthat gine),at8weeks,andat6months:theCGI-S
patientsonlamotrigineexperiencedmoreimprove- [NationalInstituteofMentalHealth,1970],asthe
ment,thedifferencesbetweenlamotrigineandplaceboprimaryefficacymeasure,theMADRS,andtheGlobal
werenotstatisticallysignificantonanyoftheefficacy Assessment of Functioning Scale [GAF; Luborsky,
measuresused[DeVeaugh-Geissetal.,2000;Laurenza 1962].Wepairedbaselinemeasures,priortoadding
etal.,1999;Londborgetal.,1999]. lamotrigine,withthoseat8weeksandat6months
Tolerabilityandsafetyoflamotriginehasbeen afteraddinglamotrigine,utilizingapairedt-test.
establishedinatleasteightplacebo-controlledclinical A qualified psychiatrist carried out ratings, and
trials,withanadverse-eventprofilegenerallycompar- nointerraterreliabilitymeasuresweretaken.
able withthat of placebo,when it isusedas
monotherapyor asan adjunctive therapy. Serious rash
TABLE 1. Patients’demographics
occurredrarely(0.1% incidence),andheadaches was
thecommonestsideeffect[Goodwinetal.,2004]. DemographicdataN514 M(SD)
Lamotriginecan be safely combined withmost
Age45(11.9)
psychotropic drugs [Reimers etal.,2005].
Sex(M/F)5/9
Illnessduration(years)11.5(10)
METHODS
Durationofcurrentepisode(months)20(8)
Numberoffailedantidepressanttrials4(2)
Fourteen patients,both males and femalesbetween
Numberofprevioushospitalizationsfordepression1(0.9)
ages 18 and65, with DSM-IV-R diagnosisofunipolar
Averagelamotriginedosage(mg)125(55)
depression were included inthestudy. Diagnosiswas
Numberofrelapsesduringthetrial0
Classificationoftreatmentresistancea
confirmedbytheMini-InternationalNeuropsychiatric Patients
Substitutionwithadifferentantidepressant3
Interview[MINI;SheehanandLecrubier,2001–2005].
Twoormoreantidepressantsofdifferentclass4
Onlypatients who had failed to respond toatleast
Combination/augmentation5
two 8-weektrialsof antidepressant treatment,defined
(e.g.moodstabilizersornovelantipsychotics)
as failuretorespond with 450% reductionin
ECTandtranscranialmagneticstimulation2
symptoms of depression, asmeasuredbyMontgo-
mery–A˚
sbergDepressionRatingScale[MADRS; aModifiedfromThaseandRush[1997].
DepressionandAnxietyDOI10.1002/da